Reproducible Brain Organoids for Reliable CNS Safety Assessment

CNS safety failures during GLP toxicology testing are infrequent¹, placing the burden of failure on the patient.

Brain organoids offer a promising solution by recapitulating key features of the human cortex—cell sourcing, cellular diversity, and 3D structure—enabling researchers to predict neurotoxicity before clinical trials.

In this webinar, discover how CNS-3D organoids deliver unparalleled consistency, with reproducible viability, morphology, and electrophysiology across plates and lots.

‍

Discussion Points

‍

• CNS-3D mirrors composition and maturity of the human cortex (~50% neurons, ~50% astrocytes), with a representative neuronal mix (~90% excitatory, ~10% inhibitory).
• Spontaneous electrophysiological activity provides a sensitive, translational readout for neurotoxicity.
• CNS-3D is 7.4x more predictive of human clinical outcomes than animal models and achieves 93.3% specificity.
• Uniform size (<1% CV) and standardized biology deliver reproducible results batch-to-batch and year-to-year, enabling routine adoption.

‍

Speakers

‍

Andrew LaCroix, PhD

Andrew LaCroix is a Lead Scientist at 28bio specializing in the development of iPSC-derived brain organoid models and their applications to preclinical safety and efficacy testing. Specifically, he has focused on predictive neurotoxicity assays and human-first drug discovery to reduce clinical failure rates and improve patient outcomes.

‍

Elliott Johns

Elliott Johns is the Associate Director of Marketing and Product Management at 28Bio focused on bridging scientific innovation and industry application of new approach methods to improve the prediction of clinical outcomes.

‍

Register for the Webinar

‍

‍

References

1. Walker, 2018

‍